Client News

Servier Deutschland: 30 Jahre langfristiges Engagement für Patientinnen und Patienten

AFYREN’s impact-driven bioeconomy model confirmed by B Corp™ certification

Ipsens Dysport® zeigt in Head-to-Head-Studie mit Botox® längere Wirkdauer bei Erwachsenen mit Spastizität der oberen Extremitäten

World Bronchiectasis Conference 2026 Returns to Hannover: 10 Years of Progress from Neglected Disease to Global Movement

Launch of TechBio firm, Lucera, brings decision intelligence to drug development, making it more predictable, more evidence-grounded, and more efficient

Abivax Announces Landmark Phase 3 ABTECT Maintenance Trial Results Evaluating Obefazimod in Moderately to Severely Active Ulcerative Colitis

Topadur Pharma AG Adds Senior Board Expertise with Appointment of Dr. Felix R. Ehrat and Dr. Peter Jager

M2care and ZEISS Ventures Support Maculaser Oy to Advance Pioneering Temperature-Controlled Retinal Laser Therapy

Formycon Reports Positive Operational Progress and Strong Revenue Growth in the First Quarter of 2026

Abivax Presents First Quarter 2026 Financial Results and Reports Three-Year Interim Data from Study 108, a Phase 2a/2b Open-Label Extension Trial of Obefazimod Following Dose De-Escalation in Patients with Ulcerative Colitis